Experts Video Reports: Genitourinary Cancers track
Learn about key results illustrated by slides from the sessions!
The Genitourinary Cancers track 2021 is supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.
Expert Video Report on castration sensitive and resistant prostate cancer - 2021 ASCO Annual Meeting
Reporting from 2021 ASCO Annual Meeting, Primo "Lucky" Lara reports on positive results from the VISION study testing the addition of lutetium 177 to standard of care in metastatic castration-resistant prostate cancer, and discusses the challenges of implementing nuclear medicine therapy in the clinic. He also comments on metastatic castration-sensitive prostate cancer results from the PEACE-1 study with a 2x2 factorial design of abiraterone plus prednisone and/or local radiotherapy, and results from the SWOG S1216 study comparing ADT plus TAK-700 vs ADT plus bicalutamide.
Expert video report on Urothelial Carcinoma from 2021 Genitourinary Cancers Symposium
Reporting from the 2021 Genitourinary Cancers Symposium, Matthew Galsky features practice changing results from Urothelial Carcinoma studies testing adjuvant nivolumab after radical surgery in muscle-invasive disease with high risk for relapse, and evaluating enfortumab vedotin vs standard chemotherapy in patients with previously treated advanced disease.
Expert video report on Prostate Cancer from 2021 Genitourinary Cancers Symposium
Reporting from the 2021 Genitourinary Cancers Symposium, Karen Knudsen comments on results from CRPC studies looking at molecular determinants associated with long term response to apalutamide in the SPARTAN study, and the final results from the ACIS study testing the addition of apalutamide to abiraterone and prednisone in metastatic disease. She also gives an overview of the final results from the TITAN study testing apalutamide in metastatic castration-sensitive setting receiving ADT.
#ESMO20 Expert Video Report on prostate cancer
Reporting from the ESMO Virtual Congress 2020, Maria De Santis comments on promising therapeutic options and practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC). She emphasises the importance of testing CRPC patients for genomic alterations (BRCA1, BRCA2 or ATM) as soon as the cancer metastasises, to identify those who could benefit from targeted treatment options.
ESMO Expert video report on urothelial cancer from ASCO 2020
Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Thomas Powles comments on practice changing results in the management of urothelial cancer and new biomarker data for improved patients selection.
ESMO Congress 2019: Expert Video Report on Prostate cancer
Reporting from ESMO 2019 Congress, Johann de Bono comments on practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC).
He features the results from the CARD study on best sequence treatment and from the PROfound trial with olaparib in patients whose tumours have homologous recombination repair gene alterations. He explains the need for molecular profiling of advanced prostate cancer which may have a major impact on prostate cancer management in the future.
ASCO 2019: Expert Video Report on Prostate cancer
E. Efstathiou reports on study results presented on prostate cancer at ASCO 2019. She explains the benefits of adding hormonal agents early in the disease spectrum, and discusses the prospect of combinatorial strategies based on biomarkers selection.
AACR 2019: Expert Video Report on Liquid Biopsy
Reporting from AACR 2019 in Atlanta, F-C. Bidard comments on clinical utility of CTCs and ctDNA as biomarkers based on the results from two studies in breast and prostate cancer.
ASCO GU 2019: Expert Video Report on Prostate Cancer
Reporting from ASCO GU, Silke Gillessen (Manchester) comments on the results from major studies on Prostate Cancer that were presented during this meeting:
Abstract 140 ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer; K. Fizazi
Abstract 687: Phase 3 study of androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: The ARCHES trial; A.J. Armstrong
ASCO GU 2019: Expert Video Report on Renal Cell Carcinoma
Reporting from ASCO GU, Bradley McGregor comments on Renal cell carcinoma studies results: JAVELIN, KEYNOTE-426, CheckMate 214, KEYNOTE-427 and a phase II study of atezolizumab and bevacizumab
Track 2018: Videos reports from ESMO Congress and ASCO conference
ESMO 2018 Congress: Highlights in advanced renal cell carcinoma
Dr Robert Motzer reports on key results from ESMO 2018 Congress: LBA6_PR: JAVELIN Renal 101: a randomised, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma.
Perspectives from ASCO 2018: Advances in metastatic RCC - the CARMENA study
Arnaud Mejean reporting from ASCO 2018 explains that the CARMENA trial was designed to learn if nephrectomy is still necessary in metastatic renal cell carcinoma (mRCC)
ASCO GU: Highlights on Renal Cell Cancer: IMmotion151 and other combination studies
Reporting from ASCO GU 2018, Bernard Escudier states that the results from studies presented are likely to be practice changing for the treatment of patients with renal cell cancer (RCC), regarding first-line options and patients' selection.
ASCO GU: Highlights on non metastatic Castration-Resistant Prostate Cancer, the SPARTAN and PROSPER trials
Reporting from ASCO GU 2018, Stephane Oudard highlights two large randomised phase III studies relevant for clinical practice (SPARTAN with apalutamide and PROSPER with enzalutamide) in term of providing new treatment options for the group of patients with non-metastatic castration-resistant prostate cancer (CRPC) who are at high risk of developing metastasis.
More ESMO videos on Genitourinary Cancers from the ESMO Channel